AI + live data · analyst records & stock signals

Leaderboard Membership Builder

Connect your AI client via MCP

Endpoint (paste into an MCP client — anonymous, free, no key)

https://mcp.koalcheck.com/mcp

Or copy this and send it to your AI to set it up:

Add the "koalcheck" MCP server to my client and connect. It is a remote Streamable-HTTP server at https://mcp.koalcheck.com/mcp — connect anonymously, no API key or login needed (the free tools work right away). If my client supports a remote/HTTP MCP server directly, just use that URL. If my client config only accepts a local command (e.g. Claude Desktop's mcpServers, which rejects a bare "url"), bridge it with command "npx" and args ["-y","mcp-remote","https://mcp.koalcheck.com/mcp"]. Then tell me to fully restart the client, and list the koalcheck tools you can call. It provides US-equity research tools built on an analyst track-record engine (who has actually been right, priced vs SPY, cross-checked with SEC & FINRA).

Capabilities User guide

$AGIO

BULLISH2026-07-08

Price around the call

↑ 2026-07-08

By horizonMaturing · ~9 trading days to go

1d

✗ -4.1%

5d

✗ -9.4%

21d

…

Original post

美股翻倍哥 · 2026-07-08

🔥 美股翻倍群实盘战报！ $AGIO 6月30日实盘下跌中精准埋伏做多，今天直接暴拉18%大获全胜！👏👏👏👏 想在美股吃到大肉，就必须买在拉升前！埋伏不论从心态还是盈亏比都远比追高稳！公司简介： Agios（AGIO）是一家总部位于美国马萨诸塞州的商业期生物制药公司，专注于细胞代谢领域的科学研究，核心业务是开发治疗罕见病（尤其是罕见血液病）的创新小分子药物。核心业务：专注于丙酮酸激酶 (PK) 激活剂的开发。核心产品 Mitapivat（商品名：PYRUKYND / AQVESME），已获批用于治疗丙酮酸激酶缺乏症（PKD）以及地中海贫血（Thalassemia）。 FDA 授予优先审评资格 (Priority Review)： 2026年7月7日，FDA 接受了其主打药 Mitapivat 用于治疗镰状红细胞病 (Sickle Cell Disease) 的补充新药申请（sNDA）并给予优先审评，PDUFA 目标日期定为 2026年11月1日。如果获批，这将成为该疾病领域的首个口服 PK 激活剂，对公司而言是一个极大的商业里程碑。 #美股 #AGIO #实盘分享 $AGIO